| abstract |
The invention discloses the application of serum Slit2 as a marker for diagnosis, treatment and metastasis monitoring of colorectal cancer. The present invention confirms for the first time that the expression level of serum Slit2 in the serum of patients with colorectal cancer is significantly increased, using serum Slit2 can effectively distinguish colorectal cancer patients from healthy people, and specifically blocking the Slit2/Robo1 signal can inhibit the growth of colorectal cancer , proliferation and metastasis. Therefore, the present invention provides a new marker for diagnosis, metastasis monitoring and treatment of colorectal cancer, that is, serum Slit2, which has good early diagnosis, metastasis monitoring and early treatment effects on patients with colorectal cancer, high sensitivity, It has strong specificity and has good application prospects and broad development space in the clinical diagnosis of colorectal cancer. |